Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Breast Diseases | 28 | 2021 | 443 | 2.150 |
Why?
|
Breast | 38 | 2021 | 1970 | 1.350 |
Why?
|
Breast Neoplasms | 121 | 2021 | 20824 | 1.300 |
Why?
|
Carcinoma, Ductal, Breast | 21 | 2017 | 1100 | 0.780 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 32 | 2014 | 948 | 0.740 |
Why?
|
Tomography, Optical Coherence | 9 | 2017 | 2657 | 0.700 |
Why?
|
Carcinoma in Situ | 15 | 2005 | 806 | 0.600 |
Why?
|
Mastectomy, Segmental | 19 | 2017 | 956 | 0.480 |
Why?
|
Cancer Care Facilities | 3 | 2020 | 402 | 0.400 |
Why?
|
Pathology, Surgical | 3 | 2009 | 155 | 0.400 |
Why?
|
Neoplasm Recurrence, Local | 40 | 2019 | 9240 | 0.370 |
Why?
|
Adenoma, Oxyphilic | 1 | 2011 | 143 | 0.370 |
Why?
|
Fibrocystic Breast Disease | 7 | 2013 | 102 | 0.350 |
Why?
|
Neoplasm Staging | 19 | 2017 | 11031 | 0.340 |
Why?
|
Bone Diseases, Infectious | 1 | 2007 | 18 | 0.300 |
Why?
|
Microscopy | 4 | 2014 | 902 | 0.290 |
Why?
|
Aspergillus fumigatus | 1 | 2007 | 150 | 0.270 |
Why?
|
Pathology, Clinical | 5 | 2010 | 368 | 0.270 |
Why?
|
Lymphatic Metastasis | 15 | 2017 | 2924 | 0.260 |
Why?
|
Aspergillosis | 1 | 2007 | 235 | 0.250 |
Why?
|
Accreditation | 2 | 2019 | 452 | 0.250 |
Why?
|
Microscopy, Confocal | 3 | 2017 | 1970 | 0.250 |
Why?
|
Thyroid Neoplasms | 5 | 2016 | 2282 | 0.240 |
Why?
|
Mastectomy | 11 | 2019 | 1793 | 0.240 |
Why?
|
Hearing Tests | 1 | 2005 | 122 | 0.240 |
Why?
|
Interferometry | 1 | 2004 | 100 | 0.240 |
Why?
|
Evoked Potentials, Auditory, Brain Stem | 1 | 2005 | 250 | 0.230 |
Why?
|
Carcinoma | 10 | 2016 | 2375 | 0.230 |
Why?
|
Problem Solving | 1 | 2006 | 440 | 0.220 |
Why?
|
Carcinoma, Lobular | 5 | 2017 | 484 | 0.210 |
Why?
|
Temporal Bone | 1 | 2007 | 661 | 0.210 |
Why?
|
Thyroid Gland | 2 | 2010 | 1173 | 0.200 |
Why?
|
Immunocompromised Host | 1 | 2007 | 847 | 0.200 |
Why?
|
Biopsy | 24 | 2015 | 6755 | 0.190 |
Why?
|
Practice Guidelines as Topic | 6 | 2019 | 7282 | 0.190 |
Why?
|
Neonatal Screening | 1 | 2005 | 591 | 0.180 |
Why?
|
Female | 133 | 2021 | 380193 | 0.180 |
Why?
|
Neoplasms, Multiple Primary | 5 | 2000 | 604 | 0.180 |
Why?
|
Biopsy, Needle | 5 | 2004 | 1641 | 0.170 |
Why?
|
Imaging, Three-Dimensional | 3 | 2017 | 4042 | 0.170 |
Why?
|
Microscopy, Ultraviolet | 1 | 2018 | 3 | 0.160 |
Why?
|
Prognosis | 28 | 2020 | 29060 | 0.160 |
Why?
|
Parathyroid Neoplasms | 2 | 2011 | 245 | 0.160 |
Why?
|
Precancerous Conditions | 6 | 2012 | 975 | 0.160 |
Why?
|
Middle Aged | 77 | 2021 | 213390 | 0.160 |
Why?
|
Combined Modality Therapy | 29 | 2005 | 8642 | 0.160 |
Why?
|
Hyperplasia | 12 | 2015 | 1185 | 0.150 |
Why?
|
Hearing Loss | 1 | 2005 | 765 | 0.150 |
Why?
|
Transillumination | 1 | 2016 | 21 | 0.150 |
Why?
|
Humans | 148 | 2021 | 744366 | 0.150 |
Why?
|
Adult | 69 | 2021 | 214052 | 0.140 |
Why?
|
Societies, Medical | 5 | 2009 | 3743 | 0.140 |
Why?
|
Alcohol Drinking | 5 | 2013 | 3966 | 0.140 |
Why?
|
Hematoxylin | 1 | 2016 | 64 | 0.140 |
Why?
|
Eosine Yellowish-(YS) | 1 | 2016 | 72 | 0.140 |
Why?
|
Carcinoma, Renal Cell | 1 | 2011 | 3143 | 0.140 |
Why?
|
Lymph Nodes | 5 | 2009 | 3476 | 0.130 |
Why?
|
Specimen Handling | 2 | 2009 | 694 | 0.130 |
Why?
|
Menarche | 2 | 2021 | 516 | 0.130 |
Why?
|
Microscopy, Fluorescence, Multiphoton | 1 | 2016 | 271 | 0.130 |
Why?
|
Kidney Neoplasms | 1 | 2011 | 4262 | 0.130 |
Why?
|
Axilla | 8 | 2001 | 597 | 0.120 |
Why?
|
Image Enhancement | 3 | 2013 | 2921 | 0.120 |
Why?
|
Thyroid Diseases | 2 | 2010 | 379 | 0.120 |
Why?
|
Image Interpretation, Computer-Assisted | 2 | 2016 | 3326 | 0.110 |
Why?
|
Diagnosis, Differential | 8 | 2016 | 12961 | 0.110 |
Why?
|
Insulin-Like Growth Factor I | 2 | 2012 | 2016 | 0.110 |
Why?
|
Insulin-Like Growth Factor Binding Protein 3 | 2 | 2012 | 424 | 0.110 |
Why?
|
Risk Factors | 32 | 2021 | 72296 | 0.110 |
Why?
|
Aged | 40 | 2021 | 163288 | 0.110 |
Why?
|
Microscopy, Fluorescence | 2 | 2017 | 2700 | 0.110 |
Why?
|
Neoplasm Invasiveness | 10 | 2017 | 3616 | 0.110 |
Why?
|
Calcinosis | 5 | 2004 | 1499 | 0.100 |
Why?
|
Adenocarcinoma, Follicular | 1 | 2016 | 324 | 0.100 |
Why?
|
Nonlinear Dynamics | 1 | 2014 | 502 | 0.100 |
Why?
|
Adenoma | 2 | 2016 | 2174 | 0.100 |
Why?
|
Molecular Typing | 1 | 2011 | 106 | 0.100 |
Why?
|
Lighting | 1 | 2013 | 231 | 0.100 |
Why?
|
Spinal Diseases | 1 | 2016 | 538 | 0.100 |
Why?
|
Technetium Tc 99m Sestamibi | 2 | 2002 | 177 | 0.100 |
Why?
|
Carcinoma, Papillary | 3 | 2016 | 783 | 0.090 |
Why?
|
Hyperparathyroidism, Primary | 2 | 2011 | 160 | 0.090 |
Why?
|
Pattern Recognition, Automated | 1 | 2017 | 1005 | 0.090 |
Why?
|
Receptors, Progesterone | 6 | 2011 | 1098 | 0.090 |
Why?
|
Image Processing, Computer-Assisted | 4 | 2018 | 8949 | 0.090 |
Why?
|
Dietary Fiber | 3 | 2010 | 760 | 0.090 |
Why?
|
Diet | 4 | 2014 | 7937 | 0.090 |
Why?
|
Molecular Probe Techniques | 1 | 2010 | 119 | 0.090 |
Why?
|
Hyperparathyroidism | 1 | 2011 | 339 | 0.090 |
Why?
|
Lasers | 1 | 2013 | 952 | 0.080 |
Why?
|
Parathyroidectomy | 1 | 2011 | 235 | 0.080 |
Why?
|
Tissue Array Analysis | 4 | 2011 | 553 | 0.080 |
Why?
|
Histocytochemistry | 1 | 2010 | 719 | 0.080 |
Why?
|
Insulin-Like Growth Factor Binding Proteins | 1 | 2010 | 216 | 0.080 |
Why?
|
Odds Ratio | 10 | 2015 | 9849 | 0.080 |
Why?
|
Quality Indicators, Health Care | 1 | 2019 | 1831 | 0.080 |
Why?
|
Receptor, IGF Type 1 | 1 | 2011 | 390 | 0.080 |
Why?
|
Skin Neoplasms | 2 | 2018 | 5692 | 0.080 |
Why?
|
Adenocarcinoma | 4 | 2004 | 6364 | 0.080 |
Why?
|
Mammography | 10 | 2004 | 2475 | 0.080 |
Why?
|
Ganglia, Sympathetic | 1 | 1987 | 62 | 0.080 |
Why?
|
Nuts | 1 | 2010 | 257 | 0.080 |
Why?
|
Receptors, Estrogen | 7 | 2011 | 2190 | 0.080 |
Why?
|
Parity | 3 | 2021 | 929 | 0.070 |
Why?
|
Sensitivity and Specificity | 9 | 2017 | 14723 | 0.070 |
Why?
|
Proportional Hazards Models | 10 | 2014 | 12356 | 0.070 |
Why?
|
Patient Selection | 1 | 2019 | 4216 | 0.070 |
Why?
|
Case-Control Studies | 12 | 2021 | 21748 | 0.070 |
Why?
|
Guideline Adherence | 1 | 2016 | 2265 | 0.070 |
Why?
|
Cohort Studies | 14 | 2021 | 40559 | 0.070 |
Why?
|
Gold | 1 | 2010 | 484 | 0.070 |
Why?
|
Manuals as Topic | 1 | 2006 | 98 | 0.070 |
Why?
|
Lymph Node Excision | 6 | 2004 | 1262 | 0.070 |
Why?
|
Intestine, Large | 1 | 2005 | 71 | 0.070 |
Why?
|
Reproductive History | 2 | 2013 | 209 | 0.070 |
Why?
|
Disease-Free Survival | 4 | 2005 | 6896 | 0.060 |
Why?
|
Folic Acid | 1 | 2012 | 1300 | 0.060 |
Why?
|
Histological Techniques | 2 | 2018 | 198 | 0.060 |
Why?
|
Mississippi | 1 | 2005 | 88 | 0.060 |
Why?
|
Quality Control | 2 | 2019 | 841 | 0.060 |
Why?
|
Stereotaxic Techniques | 2 | 2004 | 536 | 0.060 |
Why?
|
Incidence | 11 | 2016 | 20952 | 0.060 |
Why?
|
Coloring Agents | 2 | 2017 | 566 | 0.060 |
Why?
|
Tomography, X-Ray Computed | 2 | 2007 | 20130 | 0.060 |
Why?
|
Neurosurgical Procedures | 1 | 2016 | 2002 | 0.060 |
Why?
|
Risk | 10 | 2012 | 9688 | 0.060 |
Why?
|
Ultrasonography, Mammary | 2 | 2004 | 250 | 0.060 |
Why?
|
Ear, Middle | 1 | 2007 | 334 | 0.060 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2019 | 3922 | 0.060 |
Why?
|
Nerve Growth Factors | 1 | 1987 | 574 | 0.060 |
Why?
|
Dietary Fats | 3 | 2014 | 2016 | 0.060 |
Why?
|
Parathyroid Hormone | 1 | 2011 | 1800 | 0.060 |
Why?
|
Aged, 80 and over | 12 | 2016 | 57776 | 0.060 |
Why?
|
Keratins | 4 | 2008 | 515 | 0.060 |
Why?
|
United States | 17 | 2017 | 69872 | 0.060 |
Why?
|
Equipment Design | 3 | 2018 | 3582 | 0.060 |
Why?
|
Microtomy | 2 | 1997 | 47 | 0.060 |
Why?
|
Necrosis | 2 | 2007 | 1643 | 0.060 |
Why?
|
Gastrointestinal Tract | 1 | 2010 | 814 | 0.060 |
Why?
|
Retrospective Studies | 21 | 2020 | 77460 | 0.060 |
Why?
|
Menopause | 4 | 2021 | 1626 | 0.050 |
Why?
|
Sampling Studies | 1 | 2004 | 623 | 0.050 |
Why?
|
Fibroadenoma | 1 | 2002 | 43 | 0.050 |
Why?
|
Prospective Studies | 18 | 2015 | 53290 | 0.050 |
Why?
|
Fatal Outcome | 1 | 2007 | 1851 | 0.050 |
Why?
|
Neoplasm, Residual | 2 | 1997 | 973 | 0.050 |
Why?
|
Neoplasm Metastasis | 6 | 2017 | 4851 | 0.050 |
Why?
|
Immunohistochemistry | 4 | 2018 | 11366 | 0.050 |
Why?
|
Medical Records | 2 | 2009 | 1413 | 0.050 |
Why?
|
Calcium | 2 | 2012 | 5755 | 0.050 |
Why?
|
Feasibility Studies | 2 | 2010 | 5077 | 0.050 |
Why?
|
Chemotherapy, Adjuvant | 4 | 2011 | 3480 | 0.050 |
Why?
|
Keratin-5 | 2 | 2011 | 46 | 0.050 |
Why?
|
Clinical Protocols | 4 | 2009 | 1461 | 0.050 |
Why?
|
Sentinel Lymph Node Biopsy | 1 | 2006 | 710 | 0.050 |
Why?
|
Radiopharmaceuticals | 2 | 2002 | 2645 | 0.050 |
Why?
|
Predictive Value of Tests | 8 | 2021 | 15078 | 0.050 |
Why?
|
Follow-Up Studies | 21 | 2020 | 39052 | 0.050 |
Why?
|
Specialty Boards | 1 | 2003 | 227 | 0.050 |
Why?
|
Physicians | 1 | 2019 | 4567 | 0.050 |
Why?
|
Vascular Endothelial Growth Factor A | 2 | 2011 | 3511 | 0.050 |
Why?
|
Estrogen Replacement Therapy | 2 | 2013 | 1203 | 0.050 |
Why?
|
Reproducibility of Results | 5 | 2017 | 19905 | 0.050 |
Why?
|
Autopsy | 1 | 2004 | 1020 | 0.050 |
Why?
|
Observer Variation | 4 | 2004 | 2593 | 0.050 |
Why?
|
Lymphatic Irradiation | 1 | 2000 | 103 | 0.050 |
Why?
|
Cell Transformation, Neoplastic | 4 | 1999 | 2943 | 0.050 |
Why?
|
Diagnostic Errors | 1 | 2007 | 1257 | 0.040 |
Why?
|
Pathology | 1 | 2003 | 272 | 0.040 |
Why?
|
Algorithms | 2 | 2017 | 13882 | 0.040 |
Why?
|
Intestine, Small | 1 | 2005 | 1240 | 0.040 |
Why?
|
Sarcoma, Kaposi | 1 | 2002 | 370 | 0.040 |
Why?
|
Actuarial Analysis | 4 | 1994 | 378 | 0.040 |
Why?
|
Elasticity | 1 | 2021 | 657 | 0.040 |
Why?
|
Bone Marrow Transplantation | 1 | 2007 | 2765 | 0.040 |
Why?
|
AIDS-Related Opportunistic Infections | 1 | 2002 | 657 | 0.040 |
Why?
|
Hearing Loss, Sensorineural | 1 | 2005 | 770 | 0.040 |
Why?
|
Vitamin D | 1 | 2012 | 3224 | 0.040 |
Why?
|
Nanoparticles | 1 | 2010 | 1905 | 0.040 |
Why?
|
Acridine Orange | 1 | 2017 | 26 | 0.040 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 1 | 2006 | 4751 | 0.040 |
Why?
|
Body Size | 1 | 2021 | 461 | 0.040 |
Why?
|
Light | 1 | 2004 | 1374 | 0.040 |
Why?
|
Mammary Neoplasms, Experimental | 2 | 1996 | 520 | 0.040 |
Why?
|
Adolescent | 11 | 2016 | 85779 | 0.040 |
Why?
|
Gene Expression | 1 | 2011 | 7798 | 0.040 |
Why?
|
Radiotherapy Dosage | 3 | 2004 | 2879 | 0.040 |
Why?
|
Risk Assessment | 5 | 2021 | 23336 | 0.040 |
Why?
|
Rhodamines | 1 | 2017 | 183 | 0.040 |
Why?
|
Nurses | 4 | 2013 | 2462 | 0.040 |
Why?
|
Treatment Failure | 2 | 2000 | 2618 | 0.040 |
Why?
|
Receptor, erbB-2 | 3 | 2011 | 2417 | 0.040 |
Why?
|
Analysis of Variance | 3 | 2021 | 6366 | 0.040 |
Why?
|
Internship and Residency | 2 | 2010 | 5791 | 0.040 |
Why?
|
Intraoperative Period | 1 | 2017 | 520 | 0.040 |
Why?
|
Contrast Media | 1 | 2010 | 5300 | 0.040 |
Why?
|
Treatment Outcome | 12 | 2011 | 63107 | 0.030 |
Why?
|
Gelsolin | 1 | 1996 | 190 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2011 | 9445 | 0.030 |
Why?
|
Adiposity | 1 | 2005 | 1806 | 0.030 |
Why?
|
HIV Infections | 1 | 2002 | 16715 | 0.030 |
Why?
|
Palpation | 2 | 2004 | 167 | 0.030 |
Why?
|
Vitamins | 1 | 2004 | 1623 | 0.030 |
Why?
|
Neoplasms | 3 | 2005 | 21696 | 0.030 |
Why?
|
Surgery, Computer-Assisted | 1 | 2004 | 1018 | 0.030 |
Why?
|
Carcinoma, Medullary | 2 | 2007 | 123 | 0.030 |
Why?
|
Regression Analysis | 5 | 2010 | 6459 | 0.030 |
Why?
|
Premenopause | 2 | 2012 | 1033 | 0.030 |
Why?
|
Adolescent Behavior | 1 | 2003 | 1151 | 0.030 |
Why?
|
Exercise | 1 | 2011 | 5615 | 0.030 |
Why?
|
Lymphoma, Non-Hodgkin | 1 | 2002 | 1381 | 0.030 |
Why?
|
Retroelements | 1 | 1996 | 164 | 0.030 |
Why?
|
Genetic Variation | 1 | 2010 | 6542 | 0.030 |
Why?
|
Academic Medical Centers | 1 | 2005 | 2760 | 0.030 |
Why?
|
Genomics | 1 | 2010 | 5717 | 0.030 |
Why?
|
Young Adult | 4 | 2016 | 56429 | 0.030 |
Why?
|
Survival Rate | 4 | 2010 | 12788 | 0.030 |
Why?
|
Receptors, Growth Factor | 1 | 1995 | 334 | 0.030 |
Why?
|
Time Factors | 10 | 2013 | 40075 | 0.030 |
Why?
|
Carbon | 1 | 1997 | 687 | 0.030 |
Why?
|
Cicatrix | 1 | 1999 | 764 | 0.030 |
Why?
|
Software | 1 | 2007 | 4441 | 0.030 |
Why?
|
Salvage Therapy | 2 | 2005 | 1275 | 0.030 |
Why?
|
Adenocarcinoma, Mucinous | 3 | 2004 | 507 | 0.030 |
Why?
|
Estrogens | 1 | 1999 | 1566 | 0.030 |
Why?
|
Cross-Sectional Studies | 3 | 2020 | 25039 | 0.030 |
Why?
|
Endothelial Growth Factors | 1 | 1995 | 694 | 0.030 |
Why?
|
Keratin-6 | 1 | 2011 | 18 | 0.030 |
Why?
|
Micronutrients | 1 | 2014 | 375 | 0.030 |
Why?
|
Lymphokines | 1 | 1995 | 949 | 0.030 |
Why?
|
Dietary Supplements | 1 | 2004 | 3296 | 0.020 |
Why?
|
Cytoplasm | 2 | 2011 | 1536 | 0.020 |
Why?
|
Multivariate Analysis | 4 | 2012 | 12244 | 0.020 |
Why?
|
Equipment Failure Analysis | 1 | 2013 | 868 | 0.020 |
Why?
|
Subrenal Capsule Assay | 1 | 1990 | 26 | 0.020 |
Why?
|
Logistic Models | 4 | 2010 | 13409 | 0.020 |
Why?
|
Nutritional Requirements | 1 | 2012 | 286 | 0.020 |
Why?
|
Body Mass Index | 3 | 2021 | 12721 | 0.020 |
Why?
|
Hybrid Cells | 1 | 1990 | 441 | 0.020 |
Why?
|
Immunoenzyme Techniques | 2 | 2010 | 1799 | 0.020 |
Why?
|
Adipose Tissue | 1 | 2002 | 3280 | 0.020 |
Why?
|
Fluorescent Dyes | 1 | 2017 | 1917 | 0.020 |
Why?
|
Diagnostic Imaging | 1 | 2004 | 3508 | 0.020 |
Why?
|
Cell Fusion | 1 | 1990 | 297 | 0.020 |
Why?
|
ROC Curve | 1 | 2017 | 3528 | 0.020 |
Why?
|
Women's Health | 3 | 2004 | 2034 | 0.020 |
Why?
|
Epithelial Cells | 2 | 1998 | 3690 | 0.020 |
Why?
|
Neurons | 1 | 1987 | 9340 | 0.020 |
Why?
|
Double-Blind Method | 2 | 1992 | 12025 | 0.020 |
Why?
|
Adrenal Medulla | 1 | 1987 | 58 | 0.020 |
Why?
|
Microscopy, Electron, Scanning | 2 | 1987 | 963 | 0.020 |
Why?
|
Age Distribution | 1 | 2013 | 2902 | 0.020 |
Why?
|
Age Factors | 6 | 2005 | 18373 | 0.020 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 1995 | 1660 | 0.020 |
Why?
|
Vasoactive Intestinal Peptide | 1 | 1987 | 179 | 0.020 |
Why?
|
Radionuclide Imaging | 2 | 2002 | 2031 | 0.020 |
Why?
|
S100 Proteins | 1 | 1987 | 259 | 0.020 |
Why?
|
Chromogranins | 1 | 1987 | 160 | 0.020 |
Why?
|
Male | 8 | 2020 | 350115 | 0.020 |
Why?
|
Family Health | 2 | 2006 | 1281 | 0.020 |
Why?
|
Radiotherapy, Adjuvant | 2 | 2004 | 1771 | 0.020 |
Why?
|
Neoplasms, Second Primary | 1 | 1993 | 1062 | 0.020 |
Why?
|
Lipoma | 1 | 1987 | 334 | 0.020 |
Why?
|
Genetic Predisposition to Disease | 1 | 2006 | 17446 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2005 | 25628 | 0.020 |
Why?
|
Postmenopause | 1 | 2013 | 2460 | 0.020 |
Why?
|
Hot Temperature | 1 | 2010 | 1356 | 0.010 |
Why?
|
Epithelium | 3 | 1999 | 1679 | 0.010 |
Why?
|
Haplotypes | 1 | 2010 | 2779 | 0.010 |
Why?
|
Neoplasm Proteins | 1 | 1996 | 3707 | 0.010 |
Why?
|
Boston | 1 | 2016 | 9312 | 0.010 |
Why?
|
Cell Membrane | 2 | 2011 | 3749 | 0.010 |
Why?
|
Antineoplastic Agents, Hormonal | 1 | 2011 | 1524 | 0.010 |
Why?
|
Biopsy, Fine-Needle | 1 | 2007 | 1094 | 0.010 |
Why?
|
Adrenal Gland Neoplasms | 1 | 1987 | 740 | 0.010 |
Why?
|
Health Surveys | 1 | 2012 | 4036 | 0.010 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2010 | 990 | 0.010 |
Why?
|
Transfection | 1 | 1990 | 5895 | 0.010 |
Why?
|
Antineoplastic Combined Chemotherapy Protocols | 3 | 1993 | 11525 | 0.010 |
Why?
|
Thyroidectomy | 1 | 2007 | 879 | 0.010 |
Why?
|
False Positive Reactions | 1 | 2004 | 980 | 0.010 |
Why?
|
Genes, erbB | 1 | 2000 | 5 | 0.010 |
Why?
|
Radiotherapy | 4 | 1990 | 1533 | 0.010 |
Why?
|
Meningioma | 1 | 1989 | 1209 | 0.010 |
Why?
|
Diet Surveys | 1 | 2004 | 1173 | 0.010 |
Why?
|
Ploidies | 1 | 2000 | 281 | 0.010 |
Why?
|
Meningeal Neoplasms | 1 | 1989 | 1241 | 0.010 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2012 | 10943 | 0.010 |
Why?
|
Certification | 1 | 2003 | 423 | 0.010 |
Why?
|
Cell Nucleus | 2 | 2005 | 2969 | 0.010 |
Why?
|
Child | 1 | 2007 | 77709 | 0.010 |
Why?
|
Survival Analysis | 3 | 2000 | 10252 | 0.010 |
Why?
|
Pregnancy | 2 | 2013 | 29144 | 0.010 |
Why?
|
DNA-Binding Proteins | 1 | 1996 | 9647 | 0.010 |
Why?
|
Vegetables | 1 | 2003 | 1182 | 0.010 |
Why?
|
Genes, p53 | 1 | 2000 | 755 | 0.010 |
Why?
|
Gene Expression Regulation | 1 | 1996 | 12073 | 0.010 |
Why?
|
Curriculum | 1 | 2010 | 3605 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2004 | 35425 | 0.010 |
Why?
|
Radiation Injuries | 1 | 1984 | 1180 | 0.010 |
Why?
|
Rats | 2 | 1996 | 24252 | 0.010 |
Why?
|
Phospholipase D | 1 | 1996 | 70 | 0.010 |
Why?
|
Teratocarcinoma | 1 | 1996 | 17 | 0.010 |
Why?
|
Cell Division | 2 | 1997 | 4569 | 0.010 |
Why?
|
Antioxidants | 1 | 2004 | 1659 | 0.010 |
Why?
|
Tumor Cells, Cultured | 2 | 1996 | 6313 | 0.010 |
Why?
|
Mice, Inbred C3H | 1 | 1996 | 964 | 0.010 |
Why?
|
Chi-Square Distribution | 1 | 2002 | 3508 | 0.010 |
Why?
|
Mammary Glands, Animal | 1 | 1996 | 276 | 0.010 |
Why?
|
Mitosis | 1 | 2000 | 1208 | 0.010 |
Why?
|
DNA, Neoplasm | 1 | 2000 | 1758 | 0.010 |
Why?
|
Blotting, Western | 2 | 1996 | 5181 | 0.010 |
Why?
|
Clinical Competence | 1 | 2010 | 4687 | 0.010 |
Why?
|
Antibodies, Monoclonal | 2 | 1988 | 9274 | 0.010 |
Why?
|
Nerve Tissue Proteins | 1 | 1987 | 4463 | 0.010 |
Why?
|
World Health Organization | 1 | 2000 | 1318 | 0.010 |
Why?
|
Stromal Cells | 1 | 1999 | 1355 | 0.010 |
Why?
|
Cells, Cultured | 2 | 1987 | 19233 | 0.010 |
Why?
|
Health Care Surveys | 1 | 2000 | 2453 | 0.010 |
Why?
|
Vascular Endothelial Growth Factors | 1 | 1995 | 772 | 0.010 |
Why?
|
Mutagenesis, Insertional | 1 | 1996 | 655 | 0.010 |
Why?
|
Prevalence | 1 | 2008 | 15221 | 0.010 |
Why?
|
Receptors, Vascular Endothelial Growth Factor | 1 | 1995 | 664 | 0.010 |
Why?
|
Family | 1 | 2002 | 3147 | 0.010 |
Why?
|
Confidence Intervals | 1 | 1997 | 2971 | 0.010 |
Why?
|
Phenotype | 1 | 2008 | 16367 | 0.010 |
Why?
|
Receptors, Cell Surface | 1 | 2000 | 2865 | 0.010 |
Why?
|
In Situ Hybridization | 1 | 1995 | 1950 | 0.010 |
Why?
|
RNA, Messenger | 2 | 1996 | 13035 | 0.010 |
Why?
|
Radioisotope Teletherapy | 1 | 1989 | 18 | 0.010 |
Why?
|
Polymorphism, Single Nucleotide | 1 | 2010 | 15520 | 0.010 |
Why?
|
Esthetics | 1 | 1991 | 306 | 0.010 |
Why?
|
Actins | 1 | 1996 | 2121 | 0.010 |
Why?
|
Adenofibroma | 1 | 1987 | 25 | 0.000 |
Why?
|
Brain Neoplasms | 1 | 1989 | 8861 | 0.000 |
Why?
|
Mice, Inbred BALB C | 1 | 1996 | 6386 | 0.000 |
Why?
|
Ganglioneuroma | 1 | 1987 | 57 | 0.000 |
Why?
|
Evaluation Studies as Topic | 1 | 1989 | 1681 | 0.000 |
Why?
|
Molecular Weight | 1 | 1988 | 2255 | 0.000 |
Why?
|
Smoking | 1 | 2002 | 8987 | 0.000 |
Why?
|
Rats, Sprague-Dawley | 1 | 1996 | 8300 | 0.000 |
Why?
|
Pheochromocytoma | 1 | 1987 | 337 | 0.000 |
Why?
|
Animals | 4 | 1996 | 168768 | 0.000 |
Why?
|
Fluorouracil | 1 | 1989 | 1619 | 0.000 |
Why?
|
Postoperative Period | 1 | 1990 | 1842 | 0.000 |
Why?
|
Mitotic Index | 1 | 1984 | 172 | 0.000 |
Why?
|
Cyclophosphamide | 1 | 1989 | 2242 | 0.000 |
Why?
|
Mice, Nude | 1 | 1990 | 3689 | 0.000 |
Why?
|
Doxorubicin | 1 | 1989 | 2234 | 0.000 |
Why?
|
Europe | 1 | 1989 | 3338 | 0.000 |
Why?
|
Methotrexate | 1 | 1989 | 1728 | 0.000 |
Why?
|
Longitudinal Studies | 1 | 1999 | 13991 | 0.000 |
Why?
|
Dose-Response Relationship, Radiation | 1 | 1983 | 876 | 0.000 |
Why?
|
Clinical Trials as Topic | 2 | 1987 | 7914 | 0.000 |
Why?
|
Hemadsorption | 1 | 1980 | 7 | 0.000 |
Why?
|
Receptors, Concanavalin A | 1 | 1980 | 11 | 0.000 |
Why?
|
Cytochalasin B | 1 | 1980 | 74 | 0.000 |
Why?
|
Concanavalin A | 1 | 1980 | 191 | 0.000 |
Why?
|
Hyaluronoglucosaminidase | 1 | 1980 | 133 | 0.000 |
Why?
|
Microbial Collagenase | 1 | 1980 | 122 | 0.000 |
Why?
|
Brachytherapy | 1 | 1988 | 1248 | 0.000 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 1996 | 8432 | 0.000 |
Why?
|
Trypsin | 1 | 1980 | 511 | 0.000 |
Why?
|
Colchicine | 1 | 1980 | 244 | 0.000 |
Why?
|
Mice | 3 | 1996 | 81201 | 0.000 |
Why?
|
Disease Progression | 1 | 1995 | 13286 | 0.000 |
Why?
|
Surface Properties | 1 | 1980 | 1184 | 0.000 |
Why?
|
Reoperation | 1 | 1987 | 4201 | 0.000 |
Why?
|
Bone Neoplasms | 1 | 1989 | 2530 | 0.000 |
Why?
|
Patient Care Team | 1 | 1987 | 2531 | 0.000 |
Why?
|
Radiography | 1 | 1987 | 7023 | 0.000 |
Why?
|
Signal Transduction | 1 | 1996 | 23404 | 0.000 |
Why?
|
Antineoplastic Agents | 1 | 1986 | 13693 | 0.000 |
Why?
|